<DOC>
	<DOCNO>NCT01802073</DOCNO>
	<brief_summary>Determine benefit oral vancomycin therapy Primary Sclerosing Cholangitis .</brief_summary>
	<brief_title>Primary Sclerosing Cholangitis With Oral Vancomycin Study Its Antimicrobial Immunomodulating Effects</brief_title>
	<detailed_description>The purpose study evaluate change fecal salivary microbiota vancomycin treatment child adults Primary Sclerosing Cholangitis ( PSC ) , identify feature host microbiota associate disease activity and/or response treatment delineate immunological effect oral vancomycin treatment PSC . This study correlate change microbiota immunological effect oral vancomycin child adult PSC . The result proposal lead new validated target diagnosis treatment PSC high impact short long term patient family .</detailed_description>
	<mesh_term>Cholangitis</mesh_term>
	<mesh_term>Cholangitis , Sclerosing</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<criteria>PSC Diagnosis : Liver biopsy and/or imaging ( MRCP , ERCP , CT , US Colonoscopy within 1 year start study 2 group : 1 . IBD ( Inflammatory bowel disease ) PSC : detail extent type IBD 2 . No IBD PSC , positive pANCA ASCA serologies indicate possible IBD . Allergy Vancomycin PSC associate IBD NO positive IBD antibody ( pANCA [ anti neutrophil cytoplasmic antibody ] ASCA [ antiSaccharomyces cerevisiae antibody ] ) Cholangiocarcinoma On oral topical ( enemas suppository ) corticosteroid , topical mesalamine , biologics ( infliximab , adalimumab , certolizumab ) .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Inflammation bile duct</keyword>
	<keyword>biliary scarring</keyword>
	<keyword>obstruction</keyword>
</DOC>